TRM Labs Acquires UK Crypto Investigations Training Company CSITech
13.6.2022 19:32:00 EEST | Business Wire | Press release
Today, TRM Labs, the blockchain intelligence company, announced the acquisition of CSITech, a global leader in crypto and blockchain investigative training. CSITech adds its nearly two decades of investigative training experience to TRM’s suite of compliance tools and service offerings for crypto business, government and law enforcement agency, and financial institution clientele.
CSITech, a UK-based firm, delivers in-person and online training on blockchain and cryptocurrency investigations. CSITech is widely recognized as the leading crypto investigations training firm and has trained international law enforcement bodies at all levels on investigative techniques and best practices for investigating cryptocurrency-related crimes.
“TRM is on a mission to bring trust and safety to the crypto economy. Providing first-rate tools and training to law enforcement and compliance professionals that help safeguard this ecosystem is a core component,” said Esteban Castaño, co-founder and CEO of TRM Labs. “We’re excited about the expanded training capabilities Nick and his team of experts will allow us to offer to our global base of customers.”
CSITech’s expertise will augment and expand TRM’s existing portfolio of training services, which includes TRM Academy – an extensive library of self-serve digital courses available to all TRM customers as a complimentary resource – and several multi-day certification courses designed to advance the skills of professionals ranging compliance practitioners who are new to crypto to experienced crypto investigators.
“We’re committed to delivering the best training and certifications to our students, clients and partners in pursuit of our tireless mission to see the crypto space become a safer and more trustworthy environment for all,” said Nick Furneaux, Managing Director at CSITech.
“The pro level courses we are delivering are for those with a high existing knowledge base, who have taken a number of existing courses available and are looking to acquire the techniques and skills to take their capabilities, services offerings and careers to the next level.”
Mr. Furneaux is an internationally renowned expert of blockchain forensics and author of Investigating Cryptocurrencies: Understanding, Extracting, and Analyzing Blockchain Evidence (2018). In 18 years of operation, CSITech established itself as the preeminent crypto investigations training provider with top law enforcement agents among its alumni. Former pupils are currently leading some of the most well known cryptocurrency investigations in the sector, including cases involving hacks against exchanges, organized crime groups and sanctions evasion.
“Since 2019, TRM Labs has constantly innovated to build a blockchain investigations tool for today’s crypto ecosystem. We at CSITech are thrilled to join TRM on its mission to build a safer financial system for billions of people and expand our capability to train the next generation of leading cryptocurrency investigators,” said Furneaux. He and other CSITech personnel join TRM’s Training and Certifications team, operating in close collaboration with TRM’s Global Investigations team led by former IRS-Criminal Investigations (IRS-CI) Special Agent Chris Janczewski, who joined TRM in March 2022.
“The cryptocurrency space is evolving at tremendous pace and requires investigators and industry leaders to educate and prepare to match the industry’s scale,” said Chris Janczewski, Head of Global Investigations for TRM. “My team and I work closely with TRM’s Training and Certifications program to ensure that the course material continues to reflect the reality of the job on the ground.”
TRM’s certifications portfolio includes a range of multi-day course offerings that can be delivered virtually or in-person: TRM Crypto Fundamentals Certification (TRM-CFC), TRM Certified Crypto Compliance Specialist (TRM-CCS), TRM Certified Investigator (TRM-CI) and TRM Advanced Crypto Investigator (TRM-ACI). For more information and to enquire about booking group or individual courses, visit the TRM website here.
About TRM Labs
TRM provides blockchain intelligence to help financial institutions, cryptocurrency businesses and public agencies detect, investigate and manage crypto-related fraud and financial crime. TRM's risk management platform includes solutions for cryptocurrency anti-money laundering (AML), transaction monitoring and wallet screening, entity risk scoring including Know-Your-VASP, and transaction tracing for investigations. These tools enable a rapidly growing cohort of organizations around the world to safely embrace cryptocurrency-related transactions, products, and partnerships. TRM is based in San Francisco, CA and is hiring across engineering, product, sales, and data science. To learn more, visit www.trmlabs.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220613005731/en/
Contact information
Media:
Rachel Saulpaugh
trm-labs@wachsman.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
